Avalyn reports Q3 2026 financial results and initiates AP03 Phase 1 study
Avalyn reported $386.6 million in cash and business progress, and initiated a Phase 1 study for the AP03 combination therapy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed